Proactive Acquisition of Key FDA Indicator: 'Human-Relevance' Data

On March 25, SillaJen announced that research findings on its next-generation platform technology, 'SJ-650,' have been officially published in 'Molecular Therapy,' a world-renowned journal in the field of gene and cell therapy. This publication, following previous article acceptances, marks a significant academic achievement, as it formally presents the mechanism of action and detailed efficacy data of SJ-650 to the international scientific community.


Through this study, SillaJen demonstrated the innovative mechanism of SJ-650, which enables the eradication of cancer cells that have spread throughout the body via repeated intravenous administration. This overcomes the inherent limitations of existing oncolytic virus therapies, which are restricted to local administration through direct injection into tumors, and is being recognized as decisive evidence that could shift the paradigm of oncolytic virus treatment.

SillaJen Publishes Research Paper on 'SJ-650' in 'Molecular Therapy' View original image

Traditionally, oncolytic virus therapies have suffered from a critical weakness: when administered intravenously, most of the viruses are eliminated by the body's immune system, such as complement and neutralizing antibodies, before reaching tumor tissue. To address this, SJ-650 is engineered to express 'CD55,' a complement regulatory protein, on the surface of the virus, effectively evading immune detection and achieving clear differentiation from existing therapies.


According to the results of this collaborative study with the research team of Professor Lee Dongseop at Seoul National University College of Medicine, SJ-650 maintains a higher level of viability than conventional oncolytic virus therapies even in environments where neutralizing antibodies are present. Furthermore, thanks to these properties, SJ-650 selectively accumulates in tumor tissue via the bloodstream and proves high efficacy by eradicating the majority of tumor cells within 24 hours after administration.


In addition, SillaJen derived specific efficacy and safety data using a metastatic cancer animal model in this study. SJ-650 not only reduced total tumor volume by over 90%, but also inhibited metastasis and extended survival duration. In contrast, no significant cell death was observed in normal tissues, and no signs of systemic toxicity appeared even after more than 20 repeated administrations, confirming excellent safety.


Notably, SJ-650 also demonstrated its reproducible ability to evade neutralizing antibodies in serum experiments using samples from actual patients with vaccinia virus antibodies. This represents the proactive acquisition of 'human-relevance' data, which the U.S. Food and Drug Administration (FDA) now emphasizes as a key indicator for Investigational New Drug (IND) approvals, and is expected to serve as crucial evidence in future global clinical approval processes.



A SillaJen representative stated, "Through this publication, the unique mechanism and technological superiority of SJ-650 have been recognized by the international scientific community," adding, "We are currently building manufacturing processes in collaboration with global CDMO companies, and based on the secured data, will focus our capabilities on global clinical entry and commercialization."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing